5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study-Reference-Cited by-同舟云学术

5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study

Published:2019-08 Issue:8 Volume:20 Page:1098-1108
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Luo Yung-Hung,Luo Lei,Wampfler Jason A,Wang Yi,Liu Dan,Chen Yuh-Min,Adjei Alex A,Midthun David E,Yang Ping

Funder

National Institutes of Health

National Institute on Aging

Taipei Veterans General Hospital-National Yang-Ming University Excellent Physician Scientists Cultivation Program

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. Global cancer statistics;Jemal;CA Cancer J Clin,2011

2. Reduced lung-cancer mortality with low-dose computed tomographic screening;N Engl J Med,2011

3. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement;Moyer;Ann Intern Med,2014

4. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force;de Koning;Ann Intern Med,2014

5. Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered?;Pinsky;J Med Screen,2012

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Study on psychological resilience and associated influencing factors in lung cancer patients with bone metastases;World Journal of Psychiatry;2024-09-19

2. Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors;Proceedings of the National Academy of Sciences;2024-08-26

3. Immune killer cells treatment for previously treated stage IV NSCLC patients;Scientific Reports;2024-08-21

4. Personalizing Therapy Outcomes through Mitogen-Activated Protein Kinase Pathway Inhibition in Non-Small Cell Lung Cancer;Biomedicines;2024-07-05

5. Hederagenin promotes lung cancer cell death by activating CHAC1-dependent ferroptosis pathway;Biochemical and Biophysical Research Communications;2024-07